Sanyuan Biotechnology(SZ:301206) Xin Lang Cai Jing·2025-12-01 07:32Core Viewpoint - The company, Shandong Sanyuan Biotechnology Co., Ltd., specializes in the research, production, and sales of erythritol and its compound products, benefiting from trends in sugar alternatives, synthetic biology, and green energy [2][7]. Group 1: Company Overview - The company was established on January 26, 2007, and went public on February 10, 2022 [7]. - Main business revenue composition includes sugar alcohols (88.22%), functional sugars (8.59%), and others (2.93%) [7]. - The company is recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating strong innovation capabilities and market share [2]. Group 2: Financial Performance - For the period from January to September 2025, the company reported revenue of 476 million yuan, a year-on-year decrease of 7.54%, and a net profit attributable to shareholders of 67.4 million yuan, down 16.80% year-on-year [7]. - Cumulative cash dividends since the company's A-share listing amount to 608 million yuan, with 473 million yuan distributed over the past three years [8]. Group 3: Market Position and Trends - The company benefits from a 69.27% share of overseas revenue, aided by the depreciation of the Renminbi [3]. - The company is involved in distributed photovoltaic power generation projects, which reduce reliance on traditional energy sources and lower greenhouse gas emissions [2]. Group 4: Stock Performance - As of December 1, the stock price increased by 0.29%, with a trading volume of 22.05 million yuan and a market capitalization of 5.606 billion yuan [1]. - The average trading cost of the stock is 29.42 yuan, with a current support level at 27.27 yuan [6].